GPN Vaccines

Canberra, Australia · Founded 2017 · Privately Held (backing)

Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. GPN Vaccines is based in Canberra, Australia and was founded in 2017. Its last reported valuation was $300 million in Jun 2024. It has raised $27.7 million across 1 recorded round; the latest was a $3.5 million seed round in Dec 2025.

Last reported valuation
$300.0M
Oct 2026
Priced at
—
Total raised
$27.7M
Last round
Seed Round
Dec 2025
What is GPN Vaccines worth?
$300.0Mlast reported valuation · Oct 2026

GPN Vaccines's last reported valuation, Jun 2024. Nothing priced has surfaced since.

Free account
More of GPN Vaccines with a free account
  • ·Watch GPN Vaccines: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

GPN Vaccines funding history

1 rounds
DateRoundRaisedPost-money
Dec 2025Seed Round$3.5M▮
Unlock post-money valuations

Membership and data by Private Market View

GPN Vaccines valuation

GPN Vaccines's last reported valuation was $300 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has GPN Vaccines raised?

GPN Vaccines has raised $27.7 million in total; 1 of its rounds is on record. The largest on record was a $3.5 million seed round in Dec 2025.

GPN Vaccines has filed 1 Form D with the SEC, most recently in Jan 2026 ($3.5 million sold to 63 investors).

How GPN Vaccines's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For GPN Vaccines, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about GPN Vaccines

What is GPN Vaccines worth?
GPN Vaccines is valued at $300.0M as of Oct 2026. GPN Vaccines's last reported valuation, Jun 2024. Nothing priced has surfaced since.
How much has GPN Vaccines raised?
GPN Vaccines has raised $27.7M in total funding across 1 recorded rounds.
When did GPN Vaccines last raise?
GPN Vaccines last raised in Dec 2025 (Seed Round), raising $3.5M.